J
Julia A. Tree
Researcher at Public Health England
Publications - 46
Citations - 2708
Julia A. Tree is an academic researcher from Public Health England. The author has contributed to research in topics: Epitope & Virus. The author has an hindex of 19, co-authored 40 publications receiving 1560 citations. Previous affiliations of Julia A. Tree include Health Protection Agency & Salisbury University.
Papers
More filters
Journal ArticleDOI
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
J. Huo,J. Huo,A. Le Bas,A. Le Bas,Reinis R. Ruza,Duyvesteyn Hme.,H. Mikolajek,Tomas Malinauskas,Tiong Kit Tan,Pramila Rijal,Pramila Rijal,Maud Dumoux,Philip N. Ward,Philip N. Ward,Jingshan Ren,D. Zhou,Peter J. Harrison,Peter J. Harrison,Miriam Weckener,Daniel K. Clare,V K Vogirala,Julika Radecke,Lucile Moynié,Yuguang Zhao,Javier Gilbert-Jaramillo,Michael L. Knight,Julia A. Tree,Karen R. Buttigieg,Naomi Coombes,Michael J. Elmore,Miles W. Carroll,Loic Carrique,Shah Pnm.,William James,Alain Townsend,Alain Townsend,David I. Stuart,Raymond J. Owens,Raymond J. Owens,James H. Naismith,James H. Naismith +40 more
TL;DR: Two nanobodies that bind SARS-CoV-2 spike RBD are shown to block interaction with receptor ACE2 and thus neutralize the virus, and have an additive effect with antibody CR3022.
Journal ArticleDOI
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Jiandong Huo,Jiandong Huo,Yuguang Zhao,Jingshan Ren,D. Zhou,Helen M. E. Duyvesteyn,Helen M. Ginn,Loic Carrique,Tomas Malinauskas,Reinis R. Ruza,Pranav N.M. Shah,Tiong Kit Tan,Pramila Rijal,Naomi Coombes,Kevin R. Bewley,Julia A. Tree,Julika Radecke,Neil G. Paterson,P Supasa,Juthathip Mongkolsapaya,Juthathip Mongkolsapaya,Gavin R. Screaton,Miles W. Carroll,Miles W. Carroll,Alain Townsend,Elizabeth E. Fry,Raymond J. Owens,Raymond J. Owens,David I. Stuart +28 more
TL;DR: It is found that the monoclonal antibody CR3022 binds the RBD tightly, neutralising SARS-CoV-2 and the crystal structure at 2.4 Å of the Fab/RBD complex is reported, suggesting that CR30 22 binding facilitates conversion to the fusion-incompetent post-fusion state.
Journal ArticleDOI
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
D. Zhou,Duyvesteyn Hme.,Chen C-P.,Huang C-G.,Huang C-G.,Chen T-H.,Shih S-R.,Shih S-R.,Lin Y-C.,Cheng C-Y.,Cheng S-H.,Huang Y-C.,Lin T-Y.,Che Ma,J. Huo,J. Huo,Loic Carrique,Tomas Malinauskas,Reinis R. Ruza,Shah Pnm.,Tiong Kit Tan,Pramila Rijal,Pramila Rijal,R F Donat,Kerry J Godwin,Karen R. Buttigieg,Julia A. Tree,Julika Radecke,Neil G. Paterson,P Supasa,Juthathip Mongkolsapaya,Juthathip Mongkolsapaya,Gavin R. Screaton,Miles W. Carroll,Miles W. Carroll,Javier Gilbert-Jaramillo,Michael L. Knight,William James,Raymond J. Owens,Raymond J. Owens,James H. Naismith,James H. Naismith,Alain Townsend,Alain Townsend,Elizabeth E. Fry,Yuguang Zhao,Jingshan Ren,David I. Stuart,Huang K-Ya.,Huang K-Ya. +49 more
TL;DR: EY6A, a neutralizing antibody isolated from a patient convalescing from COVID-19, binds the receptor binding domain of the SARS-CoV-2 spike glycoprotein with high affinity, at a location away from the binding site for the ACE2 receptor, similar to the one recognized by CR3022.
Journal ArticleDOI
Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains
TL;DR: It is found that solid carriers composed of dextran with a positive charge are the most suitable carriers for the large-scale growth of influenza A virus in MDCK cells using serum-free media.
Journal ArticleDOI
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
Tiong Kit Tan,Pramila Rijal,Pramila Rijal,Rolle Rahikainen,Anthony H. Keeble,Lisa Schimanski,Lisa Schimanski,Saira Hussain,Ruth Harvey,Hayes Jwp.,Jane C. Edwards,Rebecca K. McLean,Veronica Martini,M. Pedrera,Nazia Thakur,Carina Conceicao,Isabelle Dietrich,Holly Shelton,Anna B. Ludi,Ginette Wilsden,Clare Browning,Adrian K. Zagrajek,Dagmara Bialy,Sushant Bhat,Phoebe Stevenson-Leggett,Philippa Hollinghurst,Philippa Hollinghurst,Matthew Tully,Katy Moffat,Christopher Chiu,Ryan Waters,Ashley R. Gray,Mehreen Azhar,Valerie Mioulet,Joseph Newman,Amin S. Asfor,Alison Burman,Sylvia Crossley,John A. Hammond,Elma Tchilian,Bryan Charleston,Dalan Bailey,Tobias J. Tuthill,Simon P. Graham,Duyvesteyn Hme.,Tomas Malinauskas,Jiandong Huo,Jiandong Huo,Julia A. Tree,Karen R. Buttigieg,Raymond J. Owens,Raymond J. Owens,Miles W. Carroll,Miles W. Carroll,Rod S. Daniels,John W. McCauley,David I. Stuart,Huang K-Ya.,Huang K-Ya.,Mark Howarth,Alain Townsend,Alain Townsend +61 more
TL;DR: In this paper, a protein nanoparticle vaccine against SARS-CoV-2 was proposed based on the display of coronavirus spike glycoprotein receptor-binding domain (RBD) on a synthetic virus-like particle (VLP) platform, using SpyTag/SpyCatcher technology.